Related Experiment Video

Updated: Apr 15, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K

NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation

Takeshi Namiki1, Tomonori Yaguchi2, Kenta Nakamura3

  • 1Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan. Department of Dermatology, Tokyo Medical and Dental University Graduate School and Faculty of Medicine, Bunkyo-ku, Tokyo, Japan.

Cancer Research
|April 3, 2015
PubMed

Insights

Genetic amplification of NUAK2 in PTEN-deficient melanomas suggests CDK2 inhibitors may be effective. This study shows CDK2 blockade suppresses growth in these specific melanoma types, offering a promising therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The role of AMPK-related kinase NUAK2 in melanoma progression is established, but its therapeutic potential remains unconfirmed.
  • PTEN deficiency is frequently observed in melanomas, impacting tumor growth and survival.
  • Genetic alterations in melanoma, such as gene amplification, can drive therapeutic resistance.

Purpose of the Study:

  • To investigate the therapeutic utility of targeting CDK2 in melanomas with genetic amplification of NUAK2 and PTEN deficiency.
  • To elucidate the molecular mechanisms linking NUAK2 amplification, PTEN loss, and melanoma cell proliferation.
  • To evaluate the efficacy of CDK2 inhibitors as a targeted therapy for a specific subset of melanomas.

Main Methods:

  • Array comparative genomic hybridization (array-CGH) to identify genomic amplifications.
  • Immunohistochemistry to assess protein expression (phospho-Akt, NUAK2, CDK2) in clinical melanoma specimens.
  • Functional studies involving NUAK2 silencing, PI3K pathway inhibition, and CDK2 inhibition in melanoma cell lines.
  • In vitro and in vivo experiments to assess the anti-tumor effects of pharmacologic CDK2 inhibition.

Main Results:

  • PTEN deficiency was strongly correlated with genomic amplification of the NUAK2 locus.
  • NUAK2 expression was associated with phospho-Akt overexpression in acral melanoma samples.
  • Inactivation of the PI3K pathway and NUAK2 silencing led to controlled CDK2 expression.
  • CDK2 inactivation specifically inhibited the growth of NUAK2-amplified and PTEN-deficient melanoma cells.
  • Pharmacologic inhibition of CDK2 suppressed tumor growth in vitro and in vivo in relevant melanoma models.

Conclusions:

  • CDK2 inhibition represents a promising therapeutic strategy for melanomas characterized by NUAK2 amplification and PTEN deletion.
  • The genetic profile of melanomas, specifically NUAK2 amplification and PTEN deficiency, can guide targeted therapeutic interventions.
  • Understanding the interplay between NUAK2, PTEN, and CDK2 pathways is crucial for developing effective melanoma treatments.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.5K
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

15.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K